Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Chicago Bristol-Myers Squibb |
---|---|
Information provided by: | University of Chicago |
ClinicalTrials.gov Identifier: | NCT00739960 |
The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.
Condition | Intervention | Phase |
---|---|---|
Sarcoidosis |
Drug: Abatacept |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Sarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive Sarcoidosis |
Enrollment: | 1 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | August 2011 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Primary Inclusion Criteria:
Primary Exclusion Criteria:
United States, Illinois | |
The University of Chicago | |
Chicago, Illinois, United States, 60637 |
Principal Investigator: | Nadera J Sweiss, MD | University of Chicago |
Responsible Party: | The University of Chicago ( Nadera J. Sweiss, MD ) |
Study ID Numbers: | IRB# 15630B |
Study First Received: | August 20, 2008 |
Last Updated: | December 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00739960 |
Health Authority: | United States: Food and Drug Administration |
Lymphatic Diseases Abatacept Sarcoidosis Lymphoproliferative Disorders |
Immunologic Factors Therapeutic Uses Physiological Effects of Drugs |
Antirheumatic Agents Immunosuppressive Agents Pharmacologic Actions |